| Literature DB >> 30485362 |
Amanda L Fuchs1, Alan J Weaver1, Brian P Tripet1, Mary Cloud B Ammons1, Martin Teintze1, Valérie Copié1.
Abstract
Bald's eyesalve is an Anglo-Saxon medicinal remedy that has been used through ancient times to treat eye sty infections and may represent a source of ancientbiotics. This study assessed the efficacy of Bald's eyesalve against several strains of Staphylococcus aureus and Pseudomonas aeruginosa, including a multi-drug resistant phenotype, and identified the principal compound conveying antibacterial activity. Bald's eyesalve formulations were produced by combining garlic, onion or leek, wine, bovine bile, and brass, with specific ingredient omissions in several formulations, followed by incubation at 4 °C for 9 days. Bald's eyesalve formulation ES-GBBr exhibited the greatest antibacterial activity against S. aureus and P. aeruginosa. Fractionation of ES-GBBr using molecular size exclusion and organic solvent partitioning isolated its antibacterial activity to the small molecule nonpolar fraction, and 1D 1H NMR revealed the identity of the antibacterial agent to be allicin. Depletion of allicin from this fraction by addition of exogenous cysteine established that all observable growth inhibition originated from allicin. Quantification of allicin demonstrated that its concentration was significantly greater in ES-GBBr compared to the ES-O formulation; however, this was not due to greater yield. The antibacterial activity of allicin against S. aureus was antagonized by other ingredients within Bald's eyesalve, whereas they were additive or synergistic against P. aeruginosa. These results suggest that neither leek nor onion is necessary for the antibacterial efficacy of Bald's eyesalve against S. aureus or P. aeruginosa, and while allicin was identified as the principal antibacterial agent present, its activity is influenced differentially in the presence of additional Bald's eyesalve ingredients when used against S. aureus compared to P. aeruginosa. Ancientbiotics may provide a source of promising antibacterials; however, identifying the source of activity and assessing distinct formulations for cooperative effects are essential to using ancient remedies, such as Bald's eyesalve, effectively against drug resistant pathogens.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30485362 PMCID: PMC6261618 DOI: 10.1371/journal.pone.0208108
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Composition of Bald’s eyesalve (ES) formulations.
| ES-O | ES-L | ES-GBBr | ES-GB | ES-GBr | ES-G | |
|---|---|---|---|---|---|---|
| Garlic | + | + | + | + | + | + |
| Wine | + | + | + | + | + | + |
| Onion | + | - | - | - | - | - |
| Leek | - | + | - | - | - | - |
| Bovine bile | + | + | + | + | - | - |
| Brass | + | + | + | - | + | - |
Bald’s eyesalve was prepared by combining equal volumes (25 mL) of garlic, wine, onion or leek, and bovine bile followed by addition of brass prior to incubation at 4 °C for 9 days. + designates ingredients that were included, while - denotes those which were excluded.
a87 mg/mL dissolved in sterile water
bNine 15-mm squares of 24 gauge (0.51-mm) brass sheet metal (alloy 260)
Susceptibility of bacterial strains to crude Bald’s eyesalve formulations.
| Bacterial strains | MIC | |||
|---|---|---|---|---|
| ES-O | ES-L | ES-GBBr | ES-GB | |
| ATCC 6538 | 0.625 | 0.625 | 0.625 | 0.625 |
| LAC | 2.5 | 1.25 | 1.25 | 1.25 |
| PAO1 | 5 | 5 | 2.5 | 2.5 |
| PA215 | 10 | 5 | 2.5 | 5 |
MIC was determined using a broth microdilution method as described by the Clinical and Laboratory Standards Institute. Reported values represent the median of at least 3 biological replicates.
aMIC values indicate the concentration of Bald’s eyesalve formulation in % (v/v)
Susceptibility of bacterial strains to ES-GBBr formulation fractions.
| Bacterial strains | MIC | |||
|---|---|---|---|---|
| PRT | SM | SM-P | SM-NP | |
| ATCC 6538 | 10 (16) | 0.625 (1) | 10 (16) | 1.25 (2) |
| LAC | >40 (>32) | 1.25 (1) | 20 (16) | 2.5 (2) |
| PAO1 | >40 (>16) | 2.5 (1) | 40 (16) | 5 (2) |
| PA215 | >40 (>16) | 5 (2) | >40 (>16) | 10 (4) |
MIC was determined using a broth microdilution method as described by the Clinical and Laboratory Standards Institute. Reported values represent the median of at least 3 biological replicates.
aMIC values indicate the concentration of ES-GBBr formulation fraction in % (v/v)
bFC values indicate the fold change in the MIC relative to that of crude ES-GBBr
Fig 11H NMR analysis of ES-GBBr formulation fractions establishes presence of unknown compound(s).
Stacked 1D 1H NMR spectra (600 MHz, 10% D2O) in chemical shift regions (A) 5.1–5.6 ppm and (B) 5.75–6.1 ppm for ES-GBBr SM (black), SM-P (red), and SM-NP (blue) fractions. Asterisks indicate NMR signals from molecule(s) of interest.
Fig 2Identity of unknown determined to be an organosulfur compound originating from garlic known as allicin.
An overlay of 1D 1H NMR spectra (600 MHz, 10% D2O) in chemical shift regions (A) 5.1–5.6 ppm and (B) 5.75–6.1 ppm for an allicin standard (black) and ES-GBBr formulation SM-NP fraction (red).
Effect of allicin depletion on susceptibility of multi-drug resistant bacterial strains to ES-GBBr formulation SM-NP fraction.
| Bacterial strains | MIC | |
|---|---|---|
| Control | Allicin-Depleted | |
| LAC | 2.5 (1) | >40 (>16) |
| PA215 | 10 (1) | >40 (>4) |
MIC was determined using a broth microdilution method as described by the Clinical and Laboratory Standards Institute. Allicin depletion was conducted by addition of free cysteine and incubation for 1 hr at 4 °C prior to MIC evaluation. Control was not subjected to allicin depletion. Reported values represent the median of at least 3 biological replicates.
aMIC values indicate the concentration of ES-GBBr SM-NP fraction in % (v/v)
bFC values indicate the fold change in the MIC relative to that of ES-GBBr SM-NP fraction
Fig 3Quantitation of allicin in eyesalve formulations reveals significant differences in concentration but not overall yield.
(A) Allicin concentration (μg/mL) was determined using Chenomx small-molecule library for 600 MHz (1H Larmor frequency) magnetic field strength NMR. (B) Allicin production (mg) was calculated by accounting for volume differences between formulations. Data are presented as mean ± SD (n = 4). Significant differences (p < 0.05, one-way ANOVA, Tukey’s multiple comparisons post-test) between formulations are indicated with asterisks.
Evaluation of conjugative effects within crude ES-GBBr formulation against multi-drug resistant bacterial strains.
| Bacterial strains | MIC | Interaction | |
|---|---|---|---|
| Control | ES-GBBr | ES-GBBr | |
| LAC | 12.2 (1) | 24.3 (2) | Antagonistic |
| PA215 | 97.4 (1) | 48.7 (-2) | Additive or Synergistic |
MIC was determined using a broth microdilution method as described by the Clinical and Laboratory Standards Institute. Control MIC values were determined using an allicin standard. Reported values represent the median of at least 3 biological replicates.
aMIC values indicate the concentration of allicin in μg/mL
bFC values indicate the fold change in the MIC relative to control